Tissue regeneration through Gene therapy

TherageniX appoints Regenerative engineering pioneer, Prof. Cato Laurencin to its Scientific Advisory Board

Biomaterials, stem cells and gene therapy expert, and orthopaedic surgeon joins TherageniX’s scientific Advisory Board to advance product development and advise on company strategy.

TherageniX (www.theragenix.health) , an early-stage biotechnology company pioneering the use of gene therapy for tissue regeneration announced that it has appointed Prof. Cato Laurencin to its Scientific Advisory Board. 

Dr. Cato T. Laurencin is an orthopaedic surgeon and chemical engineer. He is the Chief Executive Officer of The Cato T. Laurencin Institute for Regenerative Engineering at UConn, an Institute named in his honor.

Dr. Laurencin is the pioneer of the field of regenerative engineering. He is an expert in biomaterials science, stem cell technology, biophysics, gene therapy, and nanotechnology. In receiving the Spingarn Medal from the NAACP, he was named the world’s foremost engineer-physician-scientist. He is an elected member of the National Academy of Sciences, the National Academy of Engineering, the National Academy of Medicine, and an elected fellow of the National Academy of Inventors. He is the first surgeon in history elected to all four national academies in the United States.

Anand Nandakumar, CEO of TherageniX commented that,

It is wonderful for a young company like TherageniX to have such a distinguished scholar and expert like Dr. Laurencin believe in our technology and join our scientific advisory board. I am personally excited to work together and learn from Dr. Laurencin and help patients in need.

Dr. Laurencin remarked,

As the Founder of the field of Regenerative Engineering, I have had a great interest in continually expanding the toolbox for regeneration. Gene therapy has tremendous potential for regeneration and our Institute’s work has confirmed its potential for regenerating bone. I look forward to guiding TherageniX in further developing this exceptional technology for clinical use.

TherageniX is a healthcare start-up built by NLC—the European healthtech venture builder, licensing the technology from the University of Nottingham and incorporated in 2022 with the support of Nottingham Technology Ventures Ltd. 

Share this article: